A Phase 1/2 interventional study of Pemetrexed Phase 1 and Cisplatin Phase 1 in Non-Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 4 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-09.
Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 126th largest by enrollment of the 223 interventional ones that give a count, is one of 20 that started in 2005, is one of 17 in phase 1/2, and was the 62nd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Shanghai Chest Hospital · Sites in China
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
227 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 148 · Phase 3 47 · Phase 4 8
First in 2001; this study’s year is marked. 20 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is below the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 64 across the 223 interventional studies. Of the 161 that completed or were terminated, 89 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 227 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 111th largest by enrollment of the 139 interventional ones that give a count, is one of 10 that started in 2005, is one of 13 in phase 1/2, and was the 54th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT05805631Taipei Veterans General Hospital, TaiwanIntrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | 2026-12-31 |
| NCT06440954Hunan Province Tumor HospitalEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
Measure the 1 year survival of non small cell lung cancer (NSCLC) patients who are being treated with pemetrexed in combination with cisplatin and radiation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Some of the requirements to be in this study are:
Exclusion Criteria:
Patients cannot participate in this study for any of the following reasons:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment included: radiation as 61-65 Gray (Gy) in 33-35 fractions if 2-phase treatment and 62-66 Gy in 31-33 fractions if 1-phase treatment; concurrent pemetrexed intravenous (IV) bolus with doses escalating from 300 milligrams per square meter (mg/m\^2) IV through 500 mg/m\^2 IV on Days 1 and 22; concurrent cisplatin 25 mg/m\^2 IV on Days 1-3 and 22-24 for Cohorts 1-3 and cisplatin 20 mg/m\^2 IV on Days 1-5 and 22-26 for Cohort 4. Participants then received 2 additional consolidation cycles repeated every 3 weeks (q3 weeks) of pemetrexed 500 mg/m\^2 IV and cisplatin 75 mg/m\^2 IV.
Drug: Pemetrexed Phase 1 · Drug: Cisplatin Phase 1 · Procedure: Radiation Therapy
Treatment included: radiation, 61-65 Gy in 33-35 fractions if 2-phase treatment and 62-66 Gy in 31-33 fractions if 1-phase treatment; concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m\^2 IV on Days 1 and 22 ; concurrent cisplatin 20 mg/m\^2 IV as determined by Phase 1 trial with cycles commencing on Days 1 and 22; 2 additional consolidation cycles (q3 weeks) of pemetrexed 500 mg/m\^2 IV and cisplatin 75 mg/m\^2 IV.
Procedure: Radiation Therapy · Drug: Pemetrexed Phase 2 · Drug: Cisplatin Phase 2
300 mg/m\^2 IV, Days 1 and 22; intermediate dose escalation level of 400 mg/m\^2 IV; then 500 mg/m\^2 IV, repeated every 21 days (q 21 days) x 2 cycles
Also known as: LY231514, Alimta
Cohorts 1-3: 25 mg/m\^2 IV, Days 1-3 and 22-24 then 75 mg/m\^2 IV, q21 days x 2 cycles Cohort 4 carried into Phase 2: 20 mg/m\^2 IV, Days 1-5 and 22-26 then 75 mg/m\^2 IV, q21 days x 2 cycles.
Phases 1 and 2: 61-65 Gy in 33-35 fractions
Concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m\^2 IV on Days 1 and 22.
Also known as: LY231514, Alimta
Phase 2 (Cohort 4 carried over from Phase 1): 20 mg/m\^2 IV, Days 1-5 and 22-26 then 75 mg/m\^2 IV, q21 days x 2 cycles.
Phase 1: Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Cisplatin and Radiation Therapy
Recommended Phase 2 MTD was highest dose at which no more than 1 of 6 participants experienced dose level toxicity (DLT). DLT=(1) Grade 3/4 dysphagia/esophagitis, leukopenia, thrombocytopenia, febrile neutropenia, fatigue/malaise, pneumonitis, dermatitis, persistent elevation of bilirubin/alkaline phosphatase/aspartate aminotransferase only if resulting in delay of radiotherapy \>1 week, delay of pemetrexed/cisplatin Cycle 2 \>2 weeks, or delay of pemetrexed/cisplatin Cycle 3 past 5 weeks after radiotherapy; (2) other Grade 3 or 4 toxicity possibly related to concurrent treatment administration.
Time frame: Baseline to measured progressive disease (PD; up to 1 year)
Phase 2: Percentage of Participants With Overall Survival (OS) at 1 Year
OS was defined as the time from date of enrollment to death due to any cause.
Time frame: Baseline to date of death from any cause (up to 1 year)
Phase 1: Number of Participants With Adverse Events (AE; Toxicity)
A listing of AEs is located in the Reported Adverse Event module.
Time frame: Baseline to measured PD (up to 1 year)
Phase 2: Percentage of Participants With Overall Survival (OS) at 2 Years and 3 Years
OS was defined as the time from date of enrollment to death due to any cause.
Time frame: Baseline and 2 years and 3 years
Phase 2: Time to Progressive Disease (PD)
Time to PD was defined as the time from study enrollment to the first date of objective disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.0) as at least a 20% increase in the sum of the longest diameter (LD) of target lesions as references the smallest sum LD recorded since treatment started or the appearance of 1 or more new lesions. Time to PD was censored at the date of death if death was due to other cause. For participants not known to have died as of the data cut-off date and who did not have PD, time to PD was censored at the last progression-free disease assessment. For participants who received subsequent cancer therapy (after discontinuation from the study therapy) before PD, time to PD was censored at the date of subsequent cancer therapy initiation.
Time frame: Baseline to measured PD (up to 3 years)
Phase 2: Percentage of Participants With Progression Free Survival (PFS)
The percentage of participants not known to have died as of the data cut-off date or last contact and who did not have PD.
Time frame: Baseline and 1 year and 2 years and 3 years
Progression Free Survival (PFS)
PFS was defined as the period from study entry until PD, death, or date of last contact. For participants not known to have died as of the data cut-off date and who did not have PD, the PFS date was censored at the last contact date (contacts considered in the determination of last progression free disease assessment).
Time frame: Baseline to measured PD (up to 36 months)
Phase 2: Percentage of Participants With Objective Tumor Response (Response Rate)
Response using Response Evaluation Criteria In Solid Tumors (RECIST 1.0). Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=small changes that do not meet above criteria. Objective response rate (%)=number of objective responders divided by the number of participants with measurable disease \* 100, where objective responders are those participants who have met criteria either for CR or PR.
Time frame: Baseline to measured PD (up to 3 years)
Phase 2: Site of Progressive Disease (PD)
Summarized participants with local (progression within the sites of initial disease)/regional (disease progression adjacent to but not within the site of initial disease at the start of treatment), distant (disease progression that is blood borne to other parts of the body, including outside the chest or involving the contralateral lung), and local + distant sites of disease. Objective PD is defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.0) as at least a 20% increase in the sum of the longest diameter (LD) of target lesions as references the smallest sum LD recorded since treatment started or the appearance of 1 or more new lesions.
Time frame: Baseline to measured PD (up to 3 years)
| Milestone | Pemetrexed/Cisplatin/Radiation Phase 1 | Pemetrexed/Cisplatin/Radiation Phase 2 |
|---|---|---|
| Started | 16 | 33 |
| Received at least 1 dose of study drug | 16 | 33 |
| Completed | 16 | 24 |
| Not completed | 0 | 9 |
| Withdrew: Adverse event | 0 | 5 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Progressive disease | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Participant ineligibility | 0 | 1 |
Recommended Phase 2 MTD was highest dose at which no more than 1 of 6 participants experienced dose level toxicity (DLT). DLT=(1) Grade 3/4 dysphagia/esophagitis, leukopenia, thrombocytopenia, febrile neutropenia, fatigue/malaise, pneumonitis, dermatitis, persistent elevation of bilirubin/alkaline phosphatase/aspartate aminotransferase only if resulting in delay of radiotherapy \>1 week, delay of pemetrexed/cisplatin Cycle 2 \>2 weeks, or delay of pemetrexed/cisplatin Cycle 3 past 5 weeks after radiotherapy; (2) other Grade 3 or 4 toxicity possibly related to concurrent treatment administration.
| milligrams per square meter (mg/m^2) | Pemetrexed/Cisplatin/Radiation Phase 1 |
|---|---|
| Concurrent Phase MTD: Pemetrexed | 500 |
| Concurrent Phase MTD: Cisplatin | 20 |
| Consolidation Phase MTD: Pemetrexed | 500 |
| Consolidation Phase MTD: Cisplatin | 75 |
OS was defined as the time from date of enrollment to death due to any cause.
| percentage of participants | Pemetrexed/Cisplatin/Radiation Phase 2 |
|---|---|
| Phase 2: Percentage of Participants With Overall Survival (OS) at 1 Year | 79.0 (66.1 to 92.0) |
A listing of AEs is located in the Reported Adverse Event module.
| participants | Pemetrexed/Cisplatin/Radiation Phase 1 |
|---|---|
| Serious Adverse Events (SAEs) | 5 |
| Other Non-serious Adverse Events (AEs) | 10 |
OS was defined as the time from date of enrollment to death due to any cause.
| percentage of participants | Pemetrexed/Cisplatin/Radiation Phase 2 |
|---|---|
| 2 years | 56.4 (40.8 to 72.0) |
| 3 years | 46.2 (30.5 to 61.8) |
Time to PD was defined as the time from study enrollment to the first date of objective disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.0) as at least a 20% increase in the sum of the longest diameter (LD) of target lesions as references the smallest sum LD recorded since treatment started or the appearance of 1 or more new lesions. Time to PD was censored at the date of death if death was due to other cause. For participants not known to have died as of the data cut-off date and who did not have PD, time to PD was censored at the last progression-free disease assessment. For participants who received subsequent cancer therapy (after discontinuation from the study therapy) before PD, time to PD was censored at the date of subsequent cancer therapy initiation.
| months | Pemetrexed/Cisplatin/Radiation Phase 2 |
|---|---|
| Phase 2: Time to Progressive Disease (PD) | 13.7 (10.2 to 19.2) |
The percentage of participants not known to have died as of the data cut-off date or last contact and who did not have PD.
| percentage of participants | Pemetrexed/Cisplatin/Radiation Phase 2 |
|---|---|
| 1 Year | 48.7 (33.0 to 64.4) |
| 2 Years | 30.8 (16.3 to 45.3) |
| 3 Years | 20.2 (7.5 to 32.9) |
PFS was defined as the period from study entry until PD, death, or date of last contact. For participants not known to have died as of the data cut-off date and who did not have PD, the PFS date was censored at the last contact date (contacts considered in the determination of last progression free disease assessment).
| months | Pemetrexed/Cisplatin/Radiation Phase 2 |
|---|---|
| Progression Free Survival (PFS) | 11.8 (9.8 to 19.2) |
Response using Response Evaluation Criteria In Solid Tumors (RECIST 1.0). Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=small changes that do not meet above criteria. Objective response rate (%)=number of objective responders divided by the number of participants with measurable disease \* 100, where objective responders are those participants who have met criteria either for CR or PR.
| percentage of participants | Pemetrexed/Cisplatin/Radiation Phase 2 |
|---|---|
| Complete Response | 0 (0 to 0) |
| Partial Response | 45.95 (29.89 to 62.00) |
Summarized participants with local (progression within the sites of initial disease)/regional (disease progression adjacent to but not within the site of initial disease at the start of treatment), distant (disease progression that is blood borne to other parts of the body, including outside the chest or involving the contralateral lung), and local + distant sites of disease. Objective PD is defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.0) as at least a 20% increase in the sum of the longest diameter (LD) of target lesions as references the smallest sum LD recorded since treatment started or the appearance of 1 or more new lesions.
| participants | Pemetrexed/Cisplatin/Radiation Phase 2 |
|---|---|
| Local/Regional | 8 |
| Distant | 17 |
| Local + Distant | 1 |
| Unknown | 1 |
Collected over Serious Adverse Events (SAE) and other Non-Serious Adverse Events were collected during study treatment only, participants received study drug for 4 cycles of 21 days per cycle.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed/Cisplatin/Radiation Phase 1 | — | 5/10 (50%) | 10/10 (100%) |
| Pemetrexed/Cisplatin/Radiation Phase 1-2 | — | 0/6 (0%) | 6/6 (100%) |
| Pemetrexed/Cisplatin/Radiation Phase 2 | — | 9/33 (27.3%) | 33/33 (100%) |
| Event | Pemetrexed/Cisplatin/Radiation Phase 1 | Pemetrexed/Cisplatin/Radiation Phase 1-2 | Pemetrexed/Cisplatin/Radiation Phase 2 |
|---|---|---|---|
| Oedema peripheralGeneral disorders | 2/10 | 0/6 | 0/33 |
| OesophagitisGastrointestinal disorders | 1/10 | 0/6 | 2/33 |
| Enterocolitis infectiousInfections and infestations | 1/10 | 0/6 | 0/33 |
| Vascular access complicationInjury, poisoning and procedural complications | 1/10 | 0/6 | 0/33 |
| Blood creatinine increasedInvestigations | 1/10 | 0/6 | 0/33 |
| Haemoglobin decreasedInvestigations | 1/10 | 0/6 | 0/33 |
| DehydrationMetabolism and nutrition disorders | 1/10 | 0/6 | 1/33 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/10 | 0/6 | 0/33 |
| HypertensionVascular disorders | 1/10 | 0/6 | 0/33 |
| FatigueGeneral disorders | 0/10 | 0/6 | 2/33 |
| Event | Pemetrexed/Cisplatin/Radiation Phase 1 | Pemetrexed/Cisplatin/Radiation Phase 1-2 | Pemetrexed/Cisplatin/Radiation Phase 2 |
|---|---|---|---|
| LymphopeniaBlood and lymphatic system disorders | 0/10 | 6/6 | 28/33 |
| FatigueGeneral disorders | 9/10 | 6/6 | 30/33 |
| Lymphocyte count decreasedInvestigations | 10/10 | 0/6 | 0/33 |
| Neutrophil count decreasedInvestigations | 9/10 | 6/6 | 24/33 |
| Platelet count decreasedInvestigations | 8/10 | 6/6 | 16/33 |
| White blood cell count decreasedInvestigations | 9/10 | 6/6 | 27/33 |
| CoughRespiratory, thoracic and mediastinal disorders | 10/10 | 2/6 | 15/33 |
| Blood glucose increasedInvestigations | 9/10 | 0/6 | 0/33 |
| Haemoglobin decreasedInvestigations | 9/10 | 5/6 | 26/33 |
| NauseaGastrointestinal disorders | 6/10 | 2/6 | 28/33 |
All participants who received study drug in Phase 1, Phase 1 and 2, or Phase 2.
| Age Continuous(years) | Pemetrexed/Cisplatin/Radiation Phase 1 | Pemetrexed/Cisplatin/Radiation Phase 1-Phase 2 | Pemetrexed/Cisplatin/Radiation Phase 2 | Total |
|---|---|---|---|---|
| Mean | 60.3 ± 8.0 | 64.3 ± 8.1 | 61.2 ± 10.5 | 61.4 ± 9.7 |
| Sex: Female, Male(Participants) | Pemetrexed/Cisplatin/Radiation Phase 1 | Pemetrexed/Cisplatin/Radiation Phase 1-Phase 2 | Pemetrexed/Cisplatin/Radiation Phase 2 | Total |
|---|---|---|---|---|
| Female | 6 | 3 | 18 | 27 |
| Male | 4 | 3 | 15 | 22 |
| Ethnicity (NIH/OMB)(Participants) | Pemetrexed/Cisplatin/Radiation Phase 1 | Pemetrexed/Cisplatin/Radiation Phase 1-Phase 2 | Pemetrexed/Cisplatin/Radiation Phase 2 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 10 | 6 | 30 | 46 |
| Unknown or Not Reported | 0 | 0 | 3 | 3 |
| Race (NIH/OMB)(Participants) | Pemetrexed/Cisplatin/Radiation Phase 1 | Pemetrexed/Cisplatin/Radiation Phase 1-Phase 2 | Pemetrexed/Cisplatin/Radiation Phase 2 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 4 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 2 | 2 |
| White | 9 | 5 | 27 | 41 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Pemetrexed/Cisplatin/Radiation Phase 1 | Pemetrexed/Cisplatin/Radiation Phase 1-Phase 2 | Pemetrexed/Cisplatin/Radiation Phase 2 | Total |
|---|---|---|---|---|
| Canada | 10 | 6 | 33 | 49 |
The record gives a start of Dec 2005, a primary completion of Aug 2010 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemetrexed
Carcinoma, Non-Small-Cell Lung →